Referências

1. Chagas AL, Mattos AA, Carrilho FJ, Et al., Brazilian society of hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma, Arq Gastroenterol, 57, pp. 1-20, (2020)
2. Yang JD, Hainaut P, Gores GJ, Et al., A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nat Rev Gastroenterol Hepatol, 16, pp. 589-604, (2019)
3. Kim HS, El-Serag HB., The Epidemiology of Hepatocellular Carcinoma in the USA, Curr Gastroenterol Rep, 21, (2019)
4. Zhang DY, Friedman SL., Fibrosis-dependent mechanisms of hepatocarcinogenesis, Hepatology, 56, pp. 769-775, (2012)
5. Forner A, Gilabert M, Bruix J, Et al., Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol, 11, pp. 525-535, (2014)
6. Forner A, Reig ME, de Lope CR, Et al., Current strategy for staging and treatment: the BCLC update and future prospects, Semin Liver Dis, 30, pp. 61-74, (2010)
7. Guglielmi A, Ruzzenente A, Conci S, Et al., Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations, World J Gastroenterol, 20, pp. 7525-7533, (2014)
8. Herman P, Perini MV, Coelho FF, Et al., Laparoscopic resection of hepatocellular carcinoma: when, why, and how? A single-center experience, J Laparoendosc Adv Surg Tech A, 24, pp. 223-228, (2014)
9. Barman PM, Su GL., Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma, Clin Liver Dis (Hoboken), 7, pp. 32-35, (2016)
10. Marrero JA, Kulik LM, Sirlin CB, Et al., Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases, Hepatology, 68, pp. 723-750, (2018)
11. Chang YJ, Chung KP, Chang YJ, Et al., Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas, Br J Surg, 103, pp. 1513-1520, (2016)
12. Glantzounis GK, Paliouras A, Stylianidi MC, Et al., The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review, Eur J Surg Oncol, 44, pp. 195-208, (2018)
13. Guo H, Wu T, Lu Q, Et al., Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages, Cancer Manag Res, 10, pp. 361-369, (2018)
14. Herman P, Lopes Fde L, Kruger JA, Et al., Is resection of hepatocellular carcinoma in the era of liver transplantation worthwile? A single center experience, Arq Gastroenterol, 53, pp. 169-174, (2016)
15. Liu PH, Lee YH, Hsia CY, Et al., Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis, Ann Surg Oncol, 21, pp. 1825-1833, (2014)
16. Glantzounis GK, Karampa A, Peristeri DV, Et al., Recent advances in the surgical management of hepatocellular carcinoma, Ann Gastroenterol, 34, pp. 453-465, (2021)
17. Choi JY, Lee JM, Sirlin CB., CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects, Radiology, 272, pp. 635-654, (2014)
18. Fonseca GM, de Mello ES, Faraj SF, Et al., Prognostic significance of poorly differentiated clusters and tumor budding in colorectal liver metastases, J Surg Oncol, 117, pp. 1364-1375, (2018)
19. Clavien PA, Barkun J, de Oliveira ML, Et al., The Clavien-Dindo classification of surgical complications: five-year experience, Ann Surg, 250, pp. 187-196, (2009)
20. Yin L, Li H, Li AJ, Et al., Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT, J Hepatol, 61, pp. 82-88, (2014)
21. Ruzzenente A, Capra F, Pachera S, Et al., Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients, J Gastrointest Surg, 13, pp. 1313-1320, (2009)
22. Reig M, Forner A, Rimola J, Et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update, J Hepatol, 76, pp. 681-693, (2022)
23. Yokoo T, Patel AD, Lev-Cohain N, Et al., Extrahepatic metastasis risk of hepatocel-lular carcinoma based on
24. α-fetoprotein and tumor staging parameters at cross-sectional imaging, Cancer Manag Res, 9, pp. 503-511, (2017)
25. Ibrahim C, Parra N, Macedo FI, Et al., Is hepatic resection better than transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis?, J Gastrointest Oncol, 10, pp. 1064-1072, (2019)
26. Lin CW, Chen YS, Lo GH, Et al., Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis, BMC Gastroenterol, 20, (2020)
27. Zhong JH, Xiang BD, Gong WF, Et al., Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization, PLoS One, 8, (2013)
28. Hsiao P, Hsieh KC, Chen YS, Et al., Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma, Medicine (Baltimore), 98, (2019)
29. Llovet JM, Ricci S, Mazzaferro V, Et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, pp. 378-390, (2008)
30. Choi GH, Shim JH, Kim MJ, Et al., Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses, Radiology, 269, pp. 603-611, (2013)
31. Lu L, Zheng P, Wu Z, Et al., Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study, Front Oncol, 11, (2021)